Brain and other central nervous system tumor statistics, 2021
Kimberly D Miller 1, Quinn T Ostrom 2 3, Carol Kruchko 2, Nirav Patil 2 4, Tarik Tihan 5, Gino Cioffi 2 6, Hannah E Fuchs 1, Kristin A Waite 2 6, Ahmedin Jemal 1, Rebecca L Siegel 1, Jill S Barnholtz-Sloan 2 6 7Affiliations expand
- PMID: 34427324
- DOI: 10.3322/caac.21693
Free article
Abstract
Brain and other central nervous system (CNS) tumors are among the most fatal cancers and account for substantial morbidity and mortality in the United States. Population-based data from the Central Brain Tumor Registry of the United States (a combined data set of the National Program of Cancer Registries [NPCR] and Surveillance, Epidemiology, and End Results [SEER] registries), NPCR, National Vital Statistics System and SEER program were analyzed to assess the contemporary burden of malignant and nonmalignant brain and other CNS tumors (hereafter brain) by histology, anatomic site, age, sex, and race/ethnicity. Malignant brain tumor incidence rates declined by 0.8% annually from 2008 to 2017 for all ages combined but increased 0.5% to 0.7% per year among children and adolescents. Malignant brain tumor incidence is highest in males and non-Hispanic White individuals, whereas the rates for nonmalignant tumors are highest in females and non-Hispanic Black individuals. Five-year relative survival for all malignant brain tumors combined increased between 1975 to 1977 and 2009 to 2015 from 23% to 36%, with larger gains among younger age groups. Less improvement among older age groups largely reflects a higher burden of glioblastoma, for which there have been few major advances in prevention, early detection, and treatment the past 4 decades. Specifically, 5-year glioblastoma survival only increased from 4% to 7% during the same time period. In addition, important survival disparities by race/ethnicity remain for childhood tumors, with the largest Black-White disparities for diffuse astrocytomas (75% vs 86% for patients diagnosed during 2009-2015) and embryonal tumors (59% vs 67%). Increased resources for the collection and reporting of timely consistent data are critical for advancing research to elucidate the causes of sex, age, and racial/ethnic differences in brain tumor occurrence, especially for rarer subtypes and among understudied populations.
Keywords: Central Brain Tumor Registry of the United States (CBTRUS); brain tumors; central nervous system tumors; epidemiology.
© 2021 The Authors. CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society.
Similar articles
- CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017.Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS.Neuro Oncol. 2020 Oct 30;22(12 Suppl 2):iv1-iv96. doi: 10.1093/neuonc/noaa200.PMID: 33123732 Free PMC article.
- Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT.Truitt G, Gittleman H, Leece R, Ostrom QT, Kruchko C, Armstrong TS, Gilbert MR, Barnholtz-Sloan JS.J Neurooncol. 2019 Aug;144(1):53-63. doi: 10.1007/s11060-019-03215-x. Epub 2019 Jun 17.PMID: 31209773 Free PMC article.
- Racial and ethnic disparities in survival of children with brain and central nervous tumors in the United States.Haizel-Cobbina J, Spector LG, Moertel C, Parsons HM.Pediatr Blood Cancer. 2021 Jan;68(1):e28738. doi: 10.1002/pbc.28738. Epub 2020 Sep 24.PMID: 32970937
- Descriptive epidemiology of germ cell tumors of the central nervous system diagnosed in the United States from 2006 to 2015.Gittleman H, Cioffi G, Vecchione-Koval T, Ostrom QT, Kruchko C, Osorio DS, Finlay JL, Barnholtz-Sloan JS.J Neurooncol. 2019 Jun;143(2):251-260. doi: 10.1007/s11060-019-03173-4. Epub 2019 Apr 25.PMID: 31025275
- CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, Barnholtz-Sloan JS.Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100. doi: 10.1093/neuonc/noz150.PMID: 31675094 Free PMC article.
Cited by 5 articles
- Brain tumor craniotomy outcomes for dual-eligible medicare and medicaid patients: a 10-year nationwide analysis.Tang OY, Clarke RA, Rivera Perla KM, Corcoran Ruiz KM, Toms SA, Weil RJ.J Neurooncol. 2022 Jan;156(2):387-398. doi: 10.1007/s11060-021-03922-4. Epub 2022 Jan 13.PMID: 35023004
- Clinical strategies to manage adult glioblastoma patients without MGMT hypermethylation.Liu D, Yang T, Ma W, Wang Y.J Cancer. 2022 Jan 1;13(1):354-363. doi: 10.7150/jca.63595. eCollection 2022.PMID: 34976195 Free PMC article. Review.
- Circulating tumor DNA profiling for childhood brain tumors: Technical challenges and evidence for utility.Liu AP, Northcott PA, Robinson GW, Gajjar A.Lab Invest. 2022 Feb;102(2):134-142. doi: 10.1038/s41374-021-00719-x. Epub 2021 Dec 21.PMID: 34934181 Review.
- The integrated multiomic diagnosis of sporadic meningiomas: a review of its clinical implications.Robert SM, Vetsa S, Nadar A, Vasandani S, Youngblood MW, Gorelick E, Jin L, Marianayagam N, Erson-Omay EZ, Günel M, Moliterno J.J Neurooncol. 2022 Jan;156(2):205-214. doi: 10.1007/s11060-021-03874-9. Epub 2021 Nov 30.PMID: 34846640 Review.
- In Vivo Study of the Efficacy and Safety of 5-Aminolevulinic Radiodynamic Therapy for Glioblastoma Fractionated Radiotherapy.Takahashi J, Nagasawa S, Doi M, Takahashi M, Narita Y, Yamamoto J, Ikemoto MJ, Iwahashi H.Int J Mol Sci. 2021 Sep 9;22(18):9762. doi: 10.3390/ijms22189762.PMID: 34575921 Free PMC article.
Editor do blog: Julio Pereira – Neurocirugião – São Paulo CRM/SP 163.113 Site para Consulta: https://www.julio-pereira.com/ Consultório: (11)99503-8838 (WhatsApp) / (11)4200-2300 Atuando no Hospital Sírio-Libanês e na BP – A Beneficência Portuguesa de São Paulo.
CONFIRA NOSSOS SITES:
Cirurgia de Coluna
Tumor Cerebral
Aneurisma Cerebral
Radiocirurgia
Neuro Cancer
WeNeuro
